153 related articles for article (PubMed ID: 27017838)
1. Developing an Anticancer Copper(II) Pro-Drug Based on the His242 Residue of the Human Serum Albumin Carrier IIA Subdomain.
Qi J; Zhang Y; Gou Y; Zhang Z; Zhou Z; Wu X; Yang F; Liang H
Mol Pharm; 2016 May; 13(5):1501-7. PubMed ID: 27017838
[TBL] [Abstract][Full Text] [Related]
2. Design of an Anticancer Copper(II) Prodrug Based on the Lys199 Residue of the Active Targeting Human Serum Albumin Nanoparticle Carrier.
Gou Y; Zhang Y; Zhang Z; Wang J; Zhou Z; Liang H; Yang F
Mol Pharm; 2017 Jun; 14(6):1861-1873. PubMed ID: 28471669
[TBL] [Abstract][Full Text] [Related]
3. Developing an anticancer copper(II) pro-drug based on the nature of cancer cell and human serum albumin carrier IIA subdomain: mouse model of breast cancer.
Gou Y; Zhang Y; Qi J; Chen S; Zhou Z; Wu X; Liang H; Yang F
Oncotarget; 2016 Oct; 7(41):67004-67019. PubMed ID: 27564255
[TBL] [Abstract][Full Text] [Related]
4. Design an anticancer copper(II) pro-drug based on the flexible IIA subdomain of human serum albumin.
Zhang Y; Zhang Z; Gou Y; Jiang M; Khan H; Zhou Z; Liang H; Yang F
J Inorg Biochem; 2017 Jul; 172():1-8. PubMed ID: 28395195
[TBL] [Abstract][Full Text] [Related]
5. Developing Anticancer Copper(II) Pro-drugs Based on the Nature of Cancer Cells and the Human Serum Albumin Carrier IIA Subdomain.
Gou Y; Qi J; Ajayi JP; Zhang Y; Zhou Z; Wu X; Yang F; Liang H
Mol Pharm; 2015 Oct; 12(10):3597-609. PubMed ID: 26354410
[TBL] [Abstract][Full Text] [Related]
6. Developing an Anticancer Copper(II) Multitarget Pro-Drug Based on the His146 Residue in the IB Subdomain of Modified Human Serum Albumin.
Wang J; Gou Y; Zhang Z; Yu P; Qi J; Qin Q; Sun H; Wu X; Liang H; Yang F
Mol Pharm; 2018 Jun; 15(6):2180-2193. PubMed ID: 29722993
[TBL] [Abstract][Full Text] [Related]
7. Developing Anticancer Ferric Prodrugs Based on the N-Donor Residues of Human Serum Albumin Carrier IIA Subdomain.
Qi J; Gou Y; Zhang Y; Yang K; Chen S; Liu L; Wu X; Wang T; Zhang W; Yang F
J Med Chem; 2016 Aug; 59(16):7497-511. PubMed ID: 27441502
[TBL] [Abstract][Full Text] [Related]
8. Folate-functionalized human serum albumin carrier for anticancer copper(II) complexes derived from natural plumbagin.
Gou Y; Zhang Z; Qi J; Liang S; Zhou Z; Yang F; Liang H
J Inorg Biochem; 2015 Dec; 153():13-22. PubMed ID: 26398432
[TBL] [Abstract][Full Text] [Related]
9. HSA IIA subdomain-based developing anticancer metal prodrug: a new and improved approach.
Yang F; Liang H
Future Med Chem; 2016; 8(2):89-91. PubMed ID: 26824398
[No Abstract] [Full Text] [Related]
10. Novel Brain-Tumor-Inhibiting Copper(II) Compound Based on a Human Serum Albumin (HSA)-Cell Penetrating Peptide Conjugate.
Zhang Z; Yu P; Gou Y; Zhang J; Li S; Cai M; Sun H; Yang F; Liang H
J Med Chem; 2019 Dec; 62(23):10630-10644. PubMed ID: 31693353
[TBL] [Abstract][Full Text] [Related]
11. Enhancing the copper(II) complexes cytotoxicity to cancer cells through bound to human serum albumin.
Gou Y; Zhang Y; Qi J; Zhou Z; Yang F; Liang H
J Inorg Biochem; 2015 Mar; 144():47-55. PubMed ID: 25573806
[TBL] [Abstract][Full Text] [Related]
12. Developing a Copper(II) Isopropyl 2-Pyridyl Ketone Thiosemicarbazone Compound Based on the IB Subdomain of Human Serum Albumin-Indomethacin Complex: Inhibiting Tumor Growth by Remodeling the Tumor Microenvironment.
Man X; Li S; Xu G; Li W; Zhu M; Zhang Z; Liang H; Yang F
J Med Chem; 2024 Apr; 67(7):5744-5757. PubMed ID: 38553427
[TBL] [Abstract][Full Text] [Related]
13. Structural basis and anticancer properties of ruthenium-based drug complexed with human serum albumin.
Zhang Y; Ho A; Yue J; Kong L; Zhou Z; Wu X; Yang F; Liang H
Eur J Med Chem; 2014 Oct; 86():449-55. PubMed ID: 25200980
[TBL] [Abstract][Full Text] [Related]
14. Developing a Multitargeted Anticancer Palladium(II) Agent Based on the His-242 Residue in the IIA Subdomain of Human Serum Albumin.
Li W; Li S; Zhang Z; Xu G; Man X; Yang F; Liang H
J Med Chem; 2023 Jul; 66(13):8564-8579. PubMed ID: 37321208
[TBL] [Abstract][Full Text] [Related]
15. Multidrug Delivery Systems Based on Human Serum Albumin for Combination Therapy with Three Anticancer Agents.
Qi J; Zhang Y; Gou Y; Lee P; Wang J; Chen S; Zhou Z; Wu X; Yang F; Liang H
Mol Pharm; 2016 Sep; 13(9):3098-105. PubMed ID: 27453125
[TBL] [Abstract][Full Text] [Related]
16. Exploring the copper(II)-aminotriazole complex-binding sites of human serum albumin.
Yang L; He L; Zhang J; An S; Zhang L
J Biol Inorg Chem; 2015 Sep; 20(6):1059-68. PubMed ID: 26239697
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, structure, protein binding of Cu(II) complexes with a tridentate NNO Schiff-base ligand.
Li M; Huang S; Ye C; Xie Y
Spectrochim Acta A Mol Biomol Spectrosc; 2015; 150():290-300. PubMed ID: 26056979
[TBL] [Abstract][Full Text] [Related]
18. Cell cytotoxicity and serum albumin binding capacity of the morin-Cu(ii) complex and its effect on deoxyribonucleic acid.
Roy AS; Samanta SK; Ghosh P; Tripathy DR; Ghosh SK; Dasgupta S
Mol Biosyst; 2016 Aug; 12(9):2818-33. PubMed ID: 27345944
[TBL] [Abstract][Full Text] [Related]
19. Human Serum Albumin-Platinum(II) Agent Nanoparticles Inhibit Tumor Growth Through Multimodal Action Against the Tumor Microenvironment.
Xu S; Luo W; Zhu M; Zhao L; Gao L; Liang H; Zhang Z; Yang F
Mol Pharm; 2024 Jan; 21(1):346-357. PubMed ID: 38015620
[TBL] [Abstract][Full Text] [Related]
20. Human Serum Albumin-Based Dual-Agent Delivery Systems for Combination Therapy: Acting against Cancer Cells and Inhibiting Neovascularization in the Tumor Microenvironment.
Zhang Z; Zhang J; Jiang M; Zhao L; Li S; Sun H; Yang F; Liang H
Mol Pharm; 2020 Apr; 17(4):1405-1414. PubMed ID: 32096645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
